The sell-side continues to weigh in on Chelsea Therapeutics (CHTP +125.2%) following Thursday's Northera panel.
Deutsche's Robyn Karnauskas lifts her target to $5 from $4, but notes the FDA could still decide against approval. Fair value is $8-9 assuming approval.
Meanwhile, Wedbush is out reiterating an Outperform rating and an $8 target. "Our impression was that the panel came to appreciate the vagaries of clinical trials for neurological disorders—especially in orphan diseases like NOH," analyst Liana Moussatos says.